A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy

Bone Marrow Transplantation

Volumn 37, Issue 11, 2006, Pages 1009-1015

  Vredenburgh, J J ^a   Madan, B ^a   Coniglio, D ^a   Ross, M ^a   Broadwater, G ^b   Niedzwiecki, D ^b   Edwards, J ^a   Marks, L ^a   Vandemark, R ^a   McDonald, C ^a   Affronti, M L ^a   Peters, W P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

Autologous transplantation; Bone metastases; Breast cancer; High dose chemotherapy

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LEUKAPHERESIS; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 33646815689     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705367     Document Type: Article

References (18)

1. Chu KC, Tarone RE, Kessler LG, Ries LA, Hankey BF, Miller BA et al. Recent trends in US breast cancer incidence, survival and mortality rates. J Nat Cancer Inst 1996; 88: 1571-1579.
2. Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastases treated with combination chemotherapy. Cancer 1986; 58: 2589-2593.
3. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61-66.
4. Dunphy FR, Spitzer G, Buzdar AU, Hortobagyi GN, Horwitz LJ, Yau JC et al. Treatment of estrogen receptor negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207-1216.
5. Antman KA, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK et al. High dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-1879.
6. Elias AD, Ibrahim J, Richardson P, Avigan D, Joyce R, Reich E et al. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: An analysis of sequential phase I/II trials from the Dana Farber/Beth Israel STAMP program. Biol Blood Marrow Transplant 2002; 8: 198-205.
7. Rowlings PA, Williams SF, Antman KH, Fields KK, Fay JW, Reed E et al. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA 1999; 282: 1335-1343.
8. Peters WP, Jones RB, Vredenburgh JJ, Sphall EJ, Hussein A, Elkordy M et al. A large, prospective, randomized trial of high dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Br Cancer Res Treat 1996; 37 (Suppl): 11 (abstract no. 35).
9. Biron P, Durand M, Delozier T, Roche T, Battista C, Fargeot P et al. High dose Thiotepa (TTP), cyclophosphamide (CPM) and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer. Results of the PEGASE 03 French Protocole. Proc ASCO 2002; 21: 42a (abstract no. 167).
10. Crump M, Gluck S, Stewart M, Levine M, Pritchard K, Kirkbride P et al. A randomized trial of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell support (ASCT) compared to standard therapy in women with metastatic breast cancer: A National Cancer Institue of Canada (NCIC) Clinical Trials Group study. Proc ASCO 2001; 20: 21a (abstract no. 82).
11. Pedrazzoli P, Ferrante P, Kulekci A, Schiavo R, DeGiorgi U, Carminati O et al. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: Critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999. Bone Marrow Transplant 2003; 32: 489-494.
12. Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JW et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplanation for metastatic breast cancer. NEJM 2000; 342: 1069-1076.
13. Jones RB, Shpall EJ, Shogan J, Olsen GA, Bast RC, Gockerman JP et al. The Duke AFM program: Intensive induction chemotherapy for metastatic breast cancer. Cancer 1990; 66: 431-436.
14. Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP et al. High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-1376.
15. Vandemark RM, Shpall EJ, Affronti ML. Bone metastases from breast cancer: Value of bone windows. J Comput Assist Tomography 1992; 16: 608-614.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
17. Petros WP, Broadwater G, Berry D, Jones RB, Vredenburgh JJ, Gilbert CJ et al. Association of high-dose cyclophosphamide, cisplatin and carmustine pharmacokinetics with survival, toxicity and dosing weight in patients with primary breast cancer. Clin Cancer Res 2002; 8: 698-705.
18. Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2002; 20: 743-750.